Our Team

Co-Founder and CEO, Aclys Bio (formerly Javelin Oncology)

Anthony (Tony) Cooper

Tony is a dedicated scientist and entrepreneur with a history of cross-disciplinary collaborative research focused on combining aspects from complementary fields to drive new value. Tony built collaborative projects among different labs both as a graduate student at the University of Chicago and as a postdoctoral research at The Scripps Research Institute. Upon making the transition to industry Tony began working at Adimab where he engineered and delivered over 1,000 potential therapeutic antibodies to partners. The programs that Tony led in his three years there have generated greater than $1.3B in upfront payments and have led to over a dozen patents in the US and abroad.  Now, as co-founder and CEO of Aclys Bio, Tony seeks to leverage his broad knowledge base and build the next generation of antibody therapeutics specially tailored to Precision Oncology applications. In his free time Tony enjoys spending time with his family in and around the woods of Vermont.

Head of R&D

Rebecca Argyros

Rebecca joined Acyls Bio in 2019 as the Head of Research and Development and leads the discovery and development of our pipeline. Rebecca has extensive experience in drug discovery and development, platform maturation and systems biology as a previous Senior Scientist at Merck and Celdara Medical. Prior to her industrial career, she researched the impact of transcription factors on multi-step phosphorelay signal transduction pathways in the Biological Sciences Department at Dartmouth College and studied Molecular Biology and Genetics at the University of New Hampshire. Rebecca spends her free time with her children, in her garden, walking in the woods with her dogs and horseback riding.

CSO

Colleen Doyle Cooper

Colleen comes from a multidisciplinary background training in immunology with a particular focus on the intersection of autoimmunity and infectious disease. Her graduate work at the University of Chicago has led to better understanding of how polyreactive antibodies are created. In her postdoctoral research at The Scripps Research Institute, Colleen built tools and laid the groundwork for creating HIV vaccine strategies that elicit broadly neutralizing antibodies. As a Principal Scientist at Celdara Medical, Colleen has been responsible for transitioning multiple assets from academic discovery through early proof-of-concept. At Aclys, Colleen designed and helped build a mammalian cell-based antibody engineering platform that has proven to be both high speed and high quality. In addition to these roles, Colleen is a member of the Scientific Advisory Board at PanSec. In her spare time, Colleen enjoys horseback riding, spending time with her family, and watching Hallmark Christmas movies.

Scientist

Andrew Coleman

Andrew is a Scientist at Aclys Bio where he conducts research generating and characterizing the next generation of precision oncology therapeutics. Prior to Aclys, Andrew was a post-doc at Dartmouth College where investigated how organelle contact sites influence synaptic transmission in nerve cells. Andrew received his BA in Neuroscience from Bowdoin College and PhD in Neuroscience from Tufts University. In his free time, he enjoys exploring the outdoors on foot or on skis and playing music.

Chairman

Jake Reder

Jake cofounded Celdara Medical with Prof. Michael Fanger as a way to bridge academic innovation and the marketplace, and currently serves as Director and CEO. Jake guided CM from a concept to the fastest growing company (across all sectors) in the state three years in a row, and is now applying these learnings to the Pandemic Security Initiative. He serves on the Boards of the New Hampshire Academy of Science, Virtici, and MBV, and is Chairman of CairnSurgical, and Javelin Oncology. Jake has lived, studied and worked in Canada, Germany, and the USA, with experiences in research, venture investing, corporate alliances and internal startups, academia, and startups. In 2017 Jake was selected by the US SBA as NH Small Business Person of the Year. Jake earned a B.Sc. with First Class Honors from the University of Waterloo, and a PhD in Chemistry as a Brown-Wetherill Fellow at Purdue University and Ludwig Maximilians Universität. Jake enjoys skiing, hiking, and sailing with his children.

Director

Eric Achtmann

Eric is a Managing Director at Global Capital Group, Director at Javelin Oncology, Founding Member of Meggitt plc’s Technology Advisory Board, as well as a Senior Advisor to McKinsey and the European Commission. Eric was previously Managing Partner at PolyTechnos Venture-Partners, a pan-European Life Science and Tech venture fund; Co-founder & Executive Chairman of V-Nova, a world leader in video compression; and Architect of Costa Coffee’s “Project Marlow”, which led to the $5.1B acquisition by Coca-Cola. He holds multiple degrees in engineering and finance, including from MIT and the MIT Sloan School of Management. He is a Professor of Practice at the MIT-founded Skoltech and former Senior Lecturer at the TU Munich and ETH Zurich. Eric enjoys flying and making great food, from German breads to kimchi.

Director

Dennis H. Langer

Dennis has served as a Director of several public and private health care companies, and served in leadership positions in several pharmaceutical, biotechnology and diagnostic companies, including Chairman and Chief Executive Officer of AdvanDx, Inc. (2013-2104), Managing Partner of Phoenix IP Ventures, LLC.(2005-2010), President, North America for Dr. Reddy’s Laboratories, Inc. (2004-2005), and from September 1994 until January 2004, Dr. Langer held several high-level positions at GlaxoSmithKline, and its predecessor, SmithKline Beecham, including most recently as a Senior Vice President of Research and Development. Previously, Dr. Langer was Chief Executive Officer and a Director of Neose Technologies, Inc., and also has held R&D and marketing positions at Searle, Abbott, and Lilly. Dr. Langer currently serves on the Board of Directors of Myriad Genetics, Inc. Previously, he served on the Boards of Dicerna Pharmaceuticals, Inc., Sirna Therapeutics, Inc. and Ception Therapeutics, Inc., which he co-founded. Dr. Langer received a B.A. in Biology from Columbia University, an M.D. from Georgetown University School of Medicine, and a J.D. from Harvard Law School.

Director

Dan Rhodes

Dan is a scientist and entrepreneur focused on precision medicine in oncology. He is the co-founder and CEO of Strata Oncology, a venture-backed precision oncology company committed to accelerating the impact of precision medicine for patients with cancer.

From 2012-2015, Dan was Vice President of Oncology for Thermo Fisher Scientific (Life Technologies) where he oversaw the development of cancer sequencing products and pharma companion diagnostic partnerships. From 2006-2012, Dan was co-founder and CEO of Compendia Bioscience, a University of Michigan spin-off formed to further develop and commercialize his thesis project, Oncomine, a cancer genome data-mining platform. Over six years, Compendia grew to 20+ pharma customers and 10,000+ users, culminating in the acquisition by Life Technologies in 2012.

Dan and his family love summers on the lake in Michigan and snow skiing in Park City, Utah.

Director

Anthony (Tony) Cooper

Tony is a dedicated scientist and entrepreneur with a history of cross-disciplinary collaborative research focused on combining aspects from complementary fields to drive new value. Tony built collaborative projects among different labs both as a graduate student at the University of Chicago and as a postdoctoral research at The Scripps Research Institute. Upon making the transition to industry Tony began working at Adimab where he engineered and delivered over 1,000 potential therapeutic antibodies to partners. The programs that Tony led in his three years there have generated greater than $1.3B in upfront payments and have led to over a dozen patents in the US and abroad.  Now, as co-founder and CEO of Aclys Bio, Tony seeks to leverage his broad knowledge base and build the next generation of antibody therapeutics specially tailored to Precision Oncology applications. In his free time Tony enjoys spending time with his family in and around the woods of Vermont.